Top Markets
Coin of the day
OncoCyte Corporation OncoCyte Corporation

OncoCyte Corporation

OCX
株式のランク #38932
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
株価
$2.84
最終同期: 2025-07-14
時価総額
$729.71K
変化(1日)
-0.70%
変化(1年)
0.00%
US
取引 OncoCyte Corporation (OCX)

カテゴリー

OncoCyte Corporation(OCX)の配当利回りの履歴
OncoCyte Corporation(銘柄コード: OCX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
OncoCyte Corporation(OCX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)